Bpi Labs Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bpi Labs (US): 1 reconciled FDA prescription therapies, $382.0M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2045-01-01
2024 CMS Total Public Spend$382.0M
2024 Medicare Part D Spend$119.3M
2024 Medicaid Spend$262.7M
California HCAI SB 17 Filings5 WAC filings (max 77.2% 2-yr change)